Leadiant Hit By Second Complaint Over Price Of CTX Drug In Europe
A second complaint has been filed, this time in Belgium, over the “excessive” price hike on Leadiant’s CDCA-containing drug for the rare genetic disorder, CTX.
You may also be interested in...
Excessive pricing is once again under the spotlight In Europe. Consumer rights organizations in Belgium and Italy have referred Biogen to the national competition authorities over “exorbitant pricing.”
Medicines prepared in pharmacies are now exempt from patent law in the Netherlands, giving pharmacists greater scope to prepare their own versions of patented medicines.
A new Dutch foundation set up to address cases of what it says are excessive drug pricing says it plans to refer Leadiant Biosciences’ CDCA product for the rare genetic disease, cerebrotendinous xanthomatosis, to the competition authorities.